genedrive plc Stock price

Equities

EHP

GB00B1VKB244

Advanced Medical Equipment & Technology

Delayed London S.E. 09:50:46 2024-03-28 am EDT 5-day change 1st Jan Change
3.5 GBX +7.69% Intraday chart for genedrive plc -19.54% -56.92%
Sales 2022 49K 61.82K Sales 2023 55K 69.39K Capitalization 17.33M 21.87M
Net income 2022 -4M -5.05M Net income 2023 -5M -6.31M EV / Sales 2022 237 x
Net cash position 2022 4.57M 5.77M Net cash position 2023 2.36M 2.98M EV / Sales 2023 272 x
P/E ratio 2022
-3.18 x
P/E ratio 2023
-3.18 x
Employees 43
Yield 2022 *
-
Yield 2023
-
Free-Float 58.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.92%
1 week-27.47%
Current month-36.90%
1 month-33.58%
3 months-61.17%
6 months-71.96%
Current year-61.17%
More quotes
1 week
2.56
Extreme 2.555
4.79
1 month
2.56
Extreme 2.555
6.13
Current year
2.56
Extreme 2.555
8.75
1 year
2.56
Extreme 2.555
40.40
3 years
2.56
Extreme 2.555
95.98
5 years
2.56
Extreme 2.555
302.60
10 years
2.56
Extreme 2.555
342.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 23-09-10
Director of Finance/CFO 45 22-04-06
Chairman 64 14-11-23
Members of the board TitleAgeSince
Chairman 64 14-11-23
Director/Board Member 50 18-08-21
Director/Board Member 66 18-04-08
More insiders
Date Price Change Volume
24-03-28 3.5 +7.69% 2 007 574
24-03-27 3.25 +4.00% 1,363,017
24-03-26 3.125 -10.71% 2,879,762
24-03-25 3.5 -6.67% 1,017,144
24-03-22 3.75 -13.79% 3,324,652

Delayed Quote London S.E., March 28, 2024 at 06:54 am EDT

More quotes
genedrive plc is a United Kingdom-based patient molecular diagnostics company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company offers products, including Genedrive MT-RNR1 ID Kit and Genedrive COV19-ID Kit. Genedrive MT-RNR1 ID Kit is a rapid genetic test in an emergency neonatal care setting. It has developed tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of hepatitis c virus (HCV), infection prior to drug administration, pathogen detection of biological military threats, and a point-of-care for COVID-19 detection system for us in areas such as healthcare, workplace screening, travel requirements, or confirmation of antigen tests.
More about the company

Chiffre d''affaires - Rate of surprise

  1. Stock
  2. Equities
  3. Stock genedrive plc - London S.E.